Shaker Investments LLC OH Purchases Shares of 8,315 Novo Nordisk A/S (NYSE:NVO)

Shaker Investments LLC OH bought a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 8,315 shares of the company's stock, valued at approximately $860,000.

Other institutional investors have also bought and sold shares of the company. Jennison Associates LLC grew its position in shares of Novo Nordisk A/S by 100.3% during the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company's stock worth $2,129,761,000 after purchasing an additional 11,727,507 shares in the last quarter. Polen Capital Management LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $718,995,000. FMR LLC lifted its holdings in shares of Novo Nordisk A/S by 122.7% in the third quarter. FMR LLC now owns 12,077,501 shares of the company's stock worth $1,098,328,000 after buying an additional 6,654,614 shares in the last quarter. Morgan Stanley boosted its position in shares of Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company's stock worth $838,021,000 after acquiring an additional 4,526,199 shares during the last quarter. Finally, Loomis Sayles & Co. L P grew its stake in Novo Nordisk A/S by 91.7% during the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company's stock valued at $827,354,000 after acquiring an additional 4,350,862 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on NVO shares. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research note on Friday. They issued an "outperform" rating and a $163.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday, April 1st. UBS Group began coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a "neutral" rating for the company. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $133.60.

Novo Nordisk A/S Trading Down 0.7 %

NVO traded down $0.88 on Friday, hitting $124.52. The company had a trading volume of 3,310,069 shares, compared to its average volume of 4,987,559. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The business's fifty day simple moving average is $125.93 and its 200 day simple moving average is $109.61. The company has a market cap of $558.79 billion, a PE ratio of 46.12, a PEG ratio of 2.08 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analysts' expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Equities research analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. This is a boost from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S's payout ratio is 48.89%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.